The U.S. Food and Drug Administration (FDA) today announced the expanded approval of Veklury® (remdesivir) to include pediatric patients 28 days of age and older weighing at least 3 kilograms with positive results of direct SARS-CoV-2 viral testing.
This FDA action makes Veklury the first approved injectable COVID-19 treatment for children less than 12 years of age.
Under the expanded indication, a three-day Veklury treatment regimen is recommended to help prevent hospitalization in non-hospitalized COVID-19 pediatric patients at high risk for COVID-19 disease progression.
Read More
